This is the new MLex platform. Existing customers should continue to use the existing MLex platform until migrated.
For any queries, please contact Customer Services or your Account Manager. Dismiss

Teva must face US antitrust claims over asthma inhalers, judge rules

( May 7, 2024, 21:06 GMT | Official Statement) -- MLex Summary: Teva Pharmaceuticals must face US claims accusing it of improperly delaying generic entry by implementing an anticompetitive scheme focused on enforcing its patents covering QVAR, a US judge ruled. District Judge Nathaniel M. Gorton denied a motion-to-dismiss based on plaintiffs’ product-hop claim being defective. “Because no generic QVAR existed at the time Teva purportedly discontinued QVAR in favor of QVAR Redihaler, asthma patients necessarily had to be transitioned onto QVAR Redihaler. The complaint states that future generic QVAR prescriptions could be automatically substituted for QVAR prescriptions but not that generic QVAR could be switched for QVAR Redihaler prescriptions or that both QVAR and QVAR Redihaler remained on the market contemporaneously for any significant period of time,” Gorton said. See document below. ...

Prepare for tomorrow’s regulatory change, today

MLex identifies risk to business wherever it emerges, with specialist reporters across the globe providing exclusive news and deep-dive analysis on the proposals, probes, enforcement actions and rulings that matter to your organization and clients, now and in the longer term.


Know what others in the room don’t, with features including:

  • Daily newsletters for Antitrust, M&A, Trade, Data Privacy & Security, Technology, AI and more
  • Custom alerts on specific filters including geographies, industries, topics and companies to suit your practice needs
  • Predictive analysis from expert journalists across North America, the UK and Europe, Latin America and Asia-Pacific
  • Curated case files bringing together news, analysis and source documents in a single timeline

Experience MLex today with a 14-day free trial.

Start Free Trial

Already a subscriber? Click here to login

Documents

Related Sections